In rhabdomyosarcoma cells, IGFBP-6 inhibited cell proliferation in a dose-dependent manner by inhibiting insulin-like growth factor II (IGF-II), which stimulates cell proliferation. Here, IGFBP6 is linked to rhabdomyosarcoma.